Biolife solutions announces preliminary fourth quarter and full year 2024 unaudited revenue from continuing operations

Fourth quarter cell processing revenue increased 7% sequentially to $20.3 million unaudited revenue for fy2024 from cell processing of $73.5 million, exceeded the high end of previously raised guidance bothell, wash. , jan. 13, 2025 /prnewswire/ -- biolife solutions , inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (cgt) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations.
BLFS Ratings Summary
BLFS Quant Ranking